Details of the Drug Combination

General Information of Drug Combination (ID: DCH4415)

Drug Combination Name
OSI-027 Verteporfin
Indication
Disease Entry Status REF
Ewing sarcoma Investigative [1]
Component Drugs OSI-027   DMJX3O8 Verteporfin   DMIY6DB
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable
High-throughput Screening Result Testing Cell Line: TC-71
Zero Interaction Potency (ZIP) Score: 23.411
Bliss Independence Score: 24.91
Loewe Additivity Score: 2.516
LHighest Single Agent (HSA) Score: 4.802

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of OSI-027
Disease Entry ICD 11 Status REF
Renal cell carcinoma 2C90 Phase 2 [2]
OSI-027 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Serine/threonine-protein kinase mTOR (mTOR) TTCJG29 MTOR_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------
Indication(s) of Verteporfin
Disease Entry ICD 11 Status REF
Choroidal neovascularization 9B76 Approved [3]
Exudative age-related macular degeneration 9B78.3Z Approved [3]
Psoriasis vulgaris EA90 Approved [4]
Verteporfin Interacts with 2 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [6]
ATP-binding cassette sub-family B member 6 (ABCB6) DTF9Y2V ABCB6_HUMAN Substrate [7]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol Cancer Ther. 2011 Aug;10(8):1394-406.
3 Verteporfin FDA Label
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44.
6 The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2. Clin Cancer Res. 2007 Apr 15;13(8):2463-70.
7 Efficient purification and reconstitution of ATP binding cassette transporter B6 (ABCB6) for functional and structural studies. J Biol Chem. 2013 Aug 2;288(31):22658-69.